Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
ACGT awards $500,000 grant to advance strategies for treating solid tumors

ACGT awards $500,000 grant to advance strategies for treating solid tumors

Scientists identify key molecules that mediate radioresistance in aggressive brain cancer

Scientists identify key molecules that mediate radioresistance in aggressive brain cancer

Researchers secure NIH funding to study differences in glioblastoma between males and females

Researchers secure NIH funding to study differences in glioblastoma between males and females

Honeybee venom induces cancer cell death in aggressive breast cancer

Honeybee venom induces cancer cell death in aggressive breast cancer

FDA grants rare disease designations to investigational brain tumor drug

FDA grants rare disease designations to investigational brain tumor drug

Researchers discover how brain cancer cells evade the body's immune system

Researchers discover how brain cancer cells evade the body's immune system

Sortilin may hold the key to developing more effective treatment for pancreatic cancer

Sortilin may hold the key to developing more effective treatment for pancreatic cancer

Removing copper from blood can destroy deadliest cancers that are resistant to immunotherapy

Removing copper from blood can destroy deadliest cancers that are resistant to immunotherapy

Multiplication of ecDNA genes present in many cancer types, drives poor patients outcomes

Multiplication of ecDNA genes present in many cancer types, drives poor patients outcomes

Study opens new therapeutic avenue for treating glioblastoma tumors

Study opens new therapeutic avenue for treating glioblastoma tumors

Researchers develop novel approach for utilizing 4D-printing of arrays to accelerate drug testing

Researchers develop novel approach for utilizing 4D-printing of arrays to accelerate drug testing

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Study: Inhibition of TLK protein stimulates the innate immune system

Study: Inhibition of TLK protein stimulates the innate immune system

NCI gives 'exceptional' rating to Penn's Abramson Cancer Center

NCI gives 'exceptional' rating to Penn's Abramson Cancer Center

Researchers use zeolite nanocrystals to deliver oxygen to brain tumors

Researchers use zeolite nanocrystals to deliver oxygen to brain tumors

Study suggests new approach to make radiation therapy more effective for glioblastoma patients

Study suggests new approach to make radiation therapy more effective for glioblastoma patients

Researchers identify targeted treatment strategy for malignant pleural mesothelioma

Researchers identify targeted treatment strategy for malignant pleural mesothelioma

Study suggests new ways to fight aggressive brain cancer

Study suggests new ways to fight aggressive brain cancer

MU offers an alternative to chemotherapy for treatment of cancer in animals and humans

MU offers an alternative to chemotherapy for treatment of cancer in animals and humans

Study shows how radiotherapy alters the behavior of immune cells in glioblastoma tumors

Study shows how radiotherapy alters the behavior of immune cells in glioblastoma tumors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.